Stockreport

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program [Yahoo! Finance]

Nasus Pharma Ltd. Ordinary Shares  (NSRX) 
PDF NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructure TEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma L [Read more]